Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validation

Abstract Crataegus azarolus L. (Rosaceae), commonly known as Mediterranean hawthorn, has long been valued in Traditional Medicine for treating cardiovascular and inflammation-related diseases, including diabetes, cancer, and rheumatism. Pharmacological benefits of Crataegus azarolus L. are notably l...

Full description

Saved in:
Bibliographic Details
Main Authors: Djoudi Boukerouis, Irene Cuadrado, Nadjet Debbache Benaida, Ana Estévez-Braun, Beatriz de las Heras, Angel Amesty, Sonsoles Hortelano
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-98901-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849713491300057088
author Djoudi Boukerouis
Irene Cuadrado
Nadjet Debbache Benaida
Ana Estévez-Braun
Beatriz de las Heras
Angel Amesty
Sonsoles Hortelano
author_facet Djoudi Boukerouis
Irene Cuadrado
Nadjet Debbache Benaida
Ana Estévez-Braun
Beatriz de las Heras
Angel Amesty
Sonsoles Hortelano
author_sort Djoudi Boukerouis
collection DOAJ
description Abstract Crataegus azarolus L. (Rosaceae), commonly known as Mediterranean hawthorn, has long been valued in Traditional Medicine for treating cardiovascular and inflammation-related diseases, including diabetes, cancer, and rheumatism. Pharmacological benefits of Crataegus azarolus L. are notably linked to its anti-inflammatory properties. Fupenzic acid, a pentacyclic triterpene isolated from its leaves, holds significant pharmacological potential that remains elusive. This study investigates the unexplored capacity of fupenzic acid as a promising anti-inflammatory agent. Using a multidisciplinary approach that integrates network pharmacology, molecular docking, in vitro assays, and predictive in silico analyses of drug-like properties, ADME, and toxicity, the mechanisms and properties of fupenzic acid have been elucidated. Network pharmacology analysis identified the potential targets for fupenzic acid, with enrichment analyses revealing key processes like inflammatory response, cytokine signaling, innate immune system, and MAPK cascade regulation. Transcription factors such as RELA, SP1, and NFKB1 were predicted to play crucial roles in its therapeutic effects. PPI network analysis underscored NF-κB as a central hub, linking these pathways to its anti-inflammatory effects. In vitro experiments demonstrated that fupenzic acid effectively suppressed inflammatory mediators like NOS-2 and COX-2, through the NF-κB pathway. Molecular docking further confirmed its favorable interaction with NF-κB, reinforcing its mechanism of action. Additionally, in silico ADMET profiling revealed favorable drug-like properties including pharmacokinetics and toxicity profiles, emphasizing its suitability as a drug candidate. This study represents a major step forward in understanding the therapeutic potential of fupenzic acid, establishing it as a distinctive and promising anti-inflammatory agent. The findings identified it as a pharmacological agent for clinical development targeting inflammation-driven diseases and also provide a foundation for future translational research.
format Article
id doaj-art-d211f8d3df4e4e71941d5856e327607f
institution DOAJ
issn 2045-2322
language English
publishDate 2025-04-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-d211f8d3df4e4e71941d5856e327607f2025-08-20T03:13:57ZengNature PortfolioScientific Reports2045-23222025-04-0115111610.1038/s41598-025-98901-4Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validationDjoudi Boukerouis0Irene Cuadrado1Nadjet Debbache Benaida2Ana Estévez-Braun3Beatriz de las Heras4Angel Amesty5Sonsoles Hortelano6Laboratoire de Biochimie Appliquée, Faculté des Sciences de la Nature et de la Vie, Université de BejaiaDepartamento de Farmacología, Farmacognosia y Botánica, Facultad de Farmacia , Universidad Complutense de Madrid (UCM)Laboratoire de Biochimie Appliquée, Faculté des Sciences de la Nature et de la Vie, Université de BejaiaDepartamento de Química Orgánica, Instituto Universitario de Bio-Orgánica Antonio González, Universidad de la LagunaDepartamento de Farmacología, Farmacognosia y Botánica, Facultad de Farmacia , Universidad Complutense de Madrid (UCM)Departamento de Química Orgánica, Instituto Universitario de Bio-Orgánica Antonio González, Universidad de la LagunaUnidad de Terapias Farmacológicas, Área de Genética Humana, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos IIIAbstract Crataegus azarolus L. (Rosaceae), commonly known as Mediterranean hawthorn, has long been valued in Traditional Medicine for treating cardiovascular and inflammation-related diseases, including diabetes, cancer, and rheumatism. Pharmacological benefits of Crataegus azarolus L. are notably linked to its anti-inflammatory properties. Fupenzic acid, a pentacyclic triterpene isolated from its leaves, holds significant pharmacological potential that remains elusive. This study investigates the unexplored capacity of fupenzic acid as a promising anti-inflammatory agent. Using a multidisciplinary approach that integrates network pharmacology, molecular docking, in vitro assays, and predictive in silico analyses of drug-like properties, ADME, and toxicity, the mechanisms and properties of fupenzic acid have been elucidated. Network pharmacology analysis identified the potential targets for fupenzic acid, with enrichment analyses revealing key processes like inflammatory response, cytokine signaling, innate immune system, and MAPK cascade regulation. Transcription factors such as RELA, SP1, and NFKB1 were predicted to play crucial roles in its therapeutic effects. PPI network analysis underscored NF-κB as a central hub, linking these pathways to its anti-inflammatory effects. In vitro experiments demonstrated that fupenzic acid effectively suppressed inflammatory mediators like NOS-2 and COX-2, through the NF-κB pathway. Molecular docking further confirmed its favorable interaction with NF-κB, reinforcing its mechanism of action. Additionally, in silico ADMET profiling revealed favorable drug-like properties including pharmacokinetics and toxicity profiles, emphasizing its suitability as a drug candidate. This study represents a major step forward in understanding the therapeutic potential of fupenzic acid, establishing it as a distinctive and promising anti-inflammatory agent. The findings identified it as a pharmacological agent for clinical development targeting inflammation-driven diseases and also provide a foundation for future translational research.https://doi.org/10.1038/s41598-025-98901-4Fupenzic acidTriterpenoidsNetwork pharmacologyInflammationMolecular dockingIn Silico ADMET
spellingShingle Djoudi Boukerouis
Irene Cuadrado
Nadjet Debbache Benaida
Ana Estévez-Braun
Beatriz de las Heras
Angel Amesty
Sonsoles Hortelano
Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validation
Scientific Reports
Fupenzic acid
Triterpenoids
Network pharmacology
Inflammation
Molecular docking
In Silico ADMET
title Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validation
title_full Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validation
title_fullStr Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validation
title_full_unstemmed Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validation
title_short Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validation
title_sort exploring the anti inflammatory activity of fupenzic acid using network pharmacology and experimental validation
topic Fupenzic acid
Triterpenoids
Network pharmacology
Inflammation
Molecular docking
In Silico ADMET
url https://doi.org/10.1038/s41598-025-98901-4
work_keys_str_mv AT djoudiboukerouis exploringtheantiinflammatoryactivityoffupenzicacidusingnetworkpharmacologyandexperimentalvalidation
AT irenecuadrado exploringtheantiinflammatoryactivityoffupenzicacidusingnetworkpharmacologyandexperimentalvalidation
AT nadjetdebbachebenaida exploringtheantiinflammatoryactivityoffupenzicacidusingnetworkpharmacologyandexperimentalvalidation
AT anaestevezbraun exploringtheantiinflammatoryactivityoffupenzicacidusingnetworkpharmacologyandexperimentalvalidation
AT beatrizdelasheras exploringtheantiinflammatoryactivityoffupenzicacidusingnetworkpharmacologyandexperimentalvalidation
AT angelamesty exploringtheantiinflammatoryactivityoffupenzicacidusingnetworkpharmacologyandexperimentalvalidation
AT sonsoleshortelano exploringtheantiinflammatoryactivityoffupenzicacidusingnetworkpharmacologyandexperimentalvalidation